21 Novembre 2026

Psicologia Punto One | Psicologia e Psicologi nel Web

Menu

Menu

SCHEDA SCIENTIFICA2026Metanalisi

Adjunctive hyperbaric oxygen therapy for post-stroke cognitive impairment: a systematic review and meta-analysis of randomized controlled trials.

Xiaosai Hu, Shurong Zhao, Dandan Zhang, Xianguo Meng

Frontiers in neurology · 2026

Abstract originale

OBJECTIVE: To evaluate the effects of adjunctive hyperbaric oxygen therapy (HBOT) on cognitive, neurological, and functional outcomes in patients with post-stroke cognitive impairment (PSCI), and explore potential sources of heterogeneity. METHODS: Eight databases were searched from inception to July 15, 2026. Randomized controlled trials (RCTs) evaluating adjunctive HBOT in patients with PSCI were included. The primary outcome was the Montreal Cognitive Assessment (MoCA); secondary outcomes included the Mini-Mental State Examination (MMSE), National Institutes of Health Stroke Scale (NIHSS), Modified Barthel Index (MBI), and Barthel Index (BI). Random-effects meta-analyses, prespecified subgroup analyses, and meta-regression were performed. Sensitivity analyses, funnel plots, Egger's tests, and GRADE assessments were conducted. RESULTS: Thirty-five RCTs involving 3,036 participants, all conducted in China, were included. Adjunctive HBOT was associated with higher MoCA scores (MD = 2.90, 95% CI: 2.47-3.33; p < 0.00001; I 2 = 84%) and MMSE scores (MD = 2.68, 95% CI: 2.20-3.16; p < 0.00001; I 2 = 83%). Improvements were also observed in NIHSS (MD = -2.61, 95% CI: -3.34 to -1.89; p < 0.00001; I 2 = 93%), MBI (MD = 6.64, 95% CI: 3.76-9.52; p < 0.00001; I 2 = 82%), and BI (MD = 8.77, 95% CI: 4.72-12.82;p < 0.00001; I 2 = 82%). No statistically significant subgroup differences were observed for MoCA (p = 0.10) or MMSE (p = 0.43). Higher baseline MoCA scores tended to be associated with smaller treatment effects in meta-regression (β = -0.1411, p = 0.0637; R 2 = 15.42%). Substantial heterogeneity remained largely unexplained. Evidence certainty was low for MoCA, MMSE, and MBI and very low for NIHSS and BI. CONCLUSION: Adjunctive HBOT may provide cognitive and functional benefits in patients with PSCI. However, substantial unexplained heterogeneity, low-to-very-low certainty of evidence, and the exclusively Chinese evidence base warrant cautious interpretation and limit generalizability. Further well-designed RCTs involving diverse populations are needed. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261473579, PROSPERO, CRD420261473579.

Parole chiave

HumansHyperbaric OxygenationRandomized Controlled Trials as TopicStrokeCognitive DysfunctionDiving and Hyperbaric Medicinecognitive functionhyperbaric oxygen therapymeta-analysispost-stroke cognitive impairmentrandomized controlled trials
Leggi il testo integrale originale

Testo estratto dalla pubblicazione: sono esclusi immagini, media, supplementi e parti soggette a diritti distinti.

Adjunctive hyperbaric oxygen therapy for post-stroke cognitive impairment: a systematic review and meta-analysis of randomized controlled trials

Objective

To evaluate the effects of adjunctive hyperbaric oxygen therapy (HBOT) on cognitive, neurological, and functional outcomes in patients with post-stroke cognitive impairment (PSCI), and explore potential sources of heterogeneity.

Methods

Eight databases were searched from inception to July 15, 2026. Randomized controlled trials (RCTs) evaluating adjunctive HBOT in patients with PSCI were included. The primary outcome was the Montreal Cognitive Assessment (MoCA); secondary outcomes included the Mini-Mental State Examination (MMSE), National Institutes of Health Stroke Scale (NIHSS), Modified Barthel Index (MBI), and Barthel Index (BI). Random-effects meta-analyses, prespecified subgroup analyses, and meta-regression were performed. Sensitivity analyses, funnel plots, Egger’s tests, and GRADE assessments were conducted.

Results

Thirty-five RCTs involving 3,036 participants, all conducted in China, were included. Adjunctive HBOT was associated with higher MoCA scores (MD = 2.90, 95% CI: 2.47–3.33; p < 0.00001; I2 = 84%) and MMSE scores (MD = 2.68, 95% CI: 2.20–3.16; p < 0.00001; I2 = 83%). Improvements were also observed in NIHSS (MD = −2.61, 95% CI: −3.34 to −1.89; p < 0.00001; I2 = 93%), MBI (MD = 6.64, 95% CI: 3.76–9.52; p < 0.00001; I2 = 82%), and BI (MD = 8.77, 95% CI: 4.72–12.82;p < 0.00001; I2 = 82%). No statistically significant subgroup differences were observed for MoCA (p = 0.10) or MMSE (p = 0.43). Higher baseline MoCA scores tended to be associated with smaller treatment effects in meta-regression (β = −0.1411, p = 0.0637; R2 = 15.42%). Substantial heterogeneity remained largely unexplained. Evidence certainty was low for MoCA, MMSE, and MBI and very low for NIHSS and BI.

Conclusion

Adjunctive HBOT may provide cognitive and functional benefits in patients with PSCI. However, substantial unexplained heterogeneity, low-to-very-low certainty of evidence, and the exclusively Chinese evidence base warrant cautious interpretation and limit generalizability. Further well-designed RCTs involving diverse populations are needed.

Systematic review registration

https://www.crd.york.ac.uk/PROSPERO/view/CRD420261473579, PROSPERO, CRD420261473579.

1Introduction

Stroke is a leading cause of death and disability worldwide and imposes a substantial global health burden (1). According to the World Stroke Organization Global Stroke Fact Sheet 2025, nearly 12 million new strokes occur annually, with approximately 93.8 million stroke survivors worldwide (2). With population aging and persistent stroke risk factors, the long-term functional and socioeconomic consequences of stroke have received increasing attention (3, 4).

Post-stroke cognitive impairment (PSCI) is a common complication of stroke, affecting multiple cognitive domains, including attention, executive function, memory, and visuospatial abilities, and is associated with reduced functional independence and quality of life (5). Recent systematic reviews and meta-analyses have reported a high prevalence of persistent cognitive impairment after stroke, highlighting PSCI as an important target in long-term stroke rehabilitation and management (6).

Current management of PSCI includes pharmacological therapy, cognitive training, physical rehabilitation, and neuromodulation (7–9). Although these interventions may improve cognitive and functional outcomes, their efficacy varies, and effective therapies targeting the underlying mechanisms of post-stroke neural injury remain limited (10). Therefore, identifying safe, feasible, and potentially beneficial therapeutic approaches is of considerable importance for promoting cognitive and functional recovery in patients with PSCI.

Hyperbaric oxygen therapy (HBOT) involves breathing high-concentration oxygen under pressures greater than atmospheric pressure, thereby increasing tissue oxygen availability. HBOT has attracted increasing attention in neurological rehabilitation and may exert neuroprotective effects by improving tissue oxygenation and modulating oxidative stress, apoptosis, mitochondrial function, and neurovascular remodeling (11–14). These neuroprotective effects may also support cognitive recovery after stroke by helping preserve neuronal function in injured brain regions, although the mechanisms underlying cognitive improvement following HBOT remain incompletely understood (13, 15). Previous preclinical and clinical studies have suggested that HBOT may improve neurological deficits and cognitive dysfunction following stroke (14, 16, 17).

However, evidence specifically addressing HBOT for PSCI remains limited. Previous systematic reviews of HBOT have primarily focused on acute ischemic stroke or broader neurological and functional outcomes, while PSCI reviews have mainly examined cognitive training, neuromodulation, and other non-pharmacological interventions (18–20). Moreover, existing HBOT trials vary in patient characteristics and treatment protocols, and the effects of HBOT on PSCI remain uncertain.

We therefore conducted a systematic review and meta-analysis of RCTs to evaluate the efficacy and safety of adjunctive HBOT in patients with PSCI and explore potential sources of between-study heterogeneity.

2Methods

This systematic review was registered prospectively with PROSPERO (registration number: CRD420261473579).

2.1Search strategy

A systematic literature search was conducted in eight electronic databases: PubMed, Embase, Cochrane Library, Web of Science, Scopus, China National Knowledge Infrastructure (CNKI), Wanfang Data, and VIP. The databases were searched from inception to July 15, 2026, for potentially eligible studies. The search strategy was developed around three core concepts: “stroke,” “post-stroke cognitive impairment,” and “hyperbaric oxygen therapy,” using a combination of controlled vocabulary and free-text terms. Chinese search terms included “脑卒中,” “脑梗死,” “卒中后认知障碍,” “认知,” and “高压氧,” together with their relevant synonyms. English search terms included “stroke,” “cerebral infarction,” “post-stroke cognitive impairment,” “cognitive,” and “hyperbaric oxygen therapy,” along with their related synonyms. Search fields and controlled vocabulary were adapted according to the characteristics of each database. In addition, the reference lists of included studies and relevant systematic reviews were manually screened to identify potentially eligible studies and minimize the possibility of missing relevant evidence. The complete search strategies and specific search strings for each database are provided in the Supplementary materials.

2.2Eligibility criteria

Inclusion criteria: (1) patients with a clinical diagnosis of stroke and concomitant cognitive impairment; (2) participants in the intervention group received HBOT; (3) participants in the control group received the same treatment as the intervention group but without HBOT; (4) the primary outcome was the Montreal Cognitive Assessment (MoCA) score, while secondary outcomes included the Mini-Mental State Examination (MMSE), National Institutes of Health Stroke Scale (NIHSS), Modified Barthel Index (MBI), Barthel Index (BI), and other cognitive or functional outcomes; and (5) the study design was a randomized controlled trial (RCT).

Exclusion criteria: (1) non-randomized controlled trials; (2) duplicate publications or multiple reports from the same study population. When multiple reports from the same study were identified, the report with the most complete information or the greatest relevance to the outcomes of interest was retained; (3) conference abstracts, reviews, and other non-original research reports; (4) studies for which the full text could not be obtained, or for which key study data remained unavailable after necessary verification and contact with the authors; (5) studies were excluded only when they did not meet the prespecified eligibility criteria; and (6) studies published in languages other than Chinese or English; (7) No geographical restrictions were imposed on study eligibility. Although no geographical restrictions were imposed, all eligible studies identified in this review were conducted in China.

2.3Study selection and data extraction

Two investigators (HXS and ZSR) independently screened the literature and extracted data, with all extracted information cross-checked for consistency. Disagreements were resolved through discussion; when consensus could not be reached, a third investigator (MXG) made the final decision. A prespecified data extraction form was used to collect relevant information, including study characteristics (study name, sample size, sex distribution, age, etc.), intervention characteristics and treatment parameters (treatment pressure and number of treatment sessions, etc.), and baseline and post-intervention data for the outcome measures. For studies with missing or unclear information, the full text and Supplementary materials were first reviewed for clarification. When necessary, the corresponding authors were contacted to obtain or verify the relevant data.

2.4Risk of bias assessment

The risk of bias in the included RCTs was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool. The tool covers five domains: bias arising from the randomization process, bias due to deviations from intended interventions, bias due to missing outcome data, bias in measurement of the outcome, and bias in selection of the reported result. Each domain was assessed using the corresponding signaling questions, and the risk of bias was classified as low risk, some concerns, or high risk according to the tool’s decision rules. An overall risk-of-bias judgment was then made based on the domain-level assessments.

2.5Statistical analysis

Statistical analyses were performed using Review Manager (RevMan) version 5.4.1 and R software version 4.4.1, with the meta package used for all statistical analyses conducted in R. Continuous outcomes were summarized as mean differences (MDs) with 95% confidence intervals (CIs). Given the potential clinical differences among studies in terms of participant characteristics, intervention protocols, and treatment procedures, random-effects meta-analyses were performed, with between-study variance (τ2) estimated using the DerSimonian–Laird (DL) method. Statistical heterogeneity across studies was assessed using Cochran’s Q test and the I2 statistic.

To explore potential sources of between-study heterogeneity, prespecified subgroup analyses were conducted according to the type of conventional treatment received by both the intervention and control groups. Studies were categorized into medication treatment, physical rehabilitation, cognitive rehabilitation, acupuncture, and repetitive transcranial magnetic stimulation (rTMS) subgroups. Differences in effect estimates between subgroups were assessed using tests for subgroup differences. Given the limited stability of effect estimates in subgroups with few studies, formal comparisons of subgroup effects were not performed for subgroups containing three or fewer studies. In addition, random-effects meta-regression analyses were performed in R to investigate associations between study characteristics and effect estimates. Prespecified potential covariates included the total number of HBOT sessions (Sessions), baseline MoCA score at study enrollment (Baseline_MoCA), and HBOT treatment pressure (Pressure). Sessions, Baseline_MoCA, and Pressure were treated as continuous variables.

Leave-one-out sensitivity analyses were performed by sequentially removing each included study and repeating the meta-analysis to assess the influence of individual studies on the pooled estimates and between-study heterogeneity, thereby evaluating the robustness of the primary findings. When at least 10 studies were available for a given outcome, funnel plots were used to assess potential small-study effects, and Egger’s linear regression test was performed for quantitative assessment. Funnel plots and Egger’s tests were not performed when fewer than 10 studies were available. A two-sided p < 0.05 was considered statistically significant, except for Egger’s test, for which p < 0.05 was considered indicative of potential small-study effects.

2.6Certainty of evidence

The certainty of evidence for the primary and important secondary outcomes was assessed using the GRADEpro GDT online tool. According to the GRADE framework, evidence from randomized controlled trials initially starts at high certainty and is assessed across five domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias. The certainty of evidence was downgraded when relevant limitations were identified, according to their severity. The overall certainty of evidence was classified into four levels: high, moderate, low, and very low.

3Results

3.1Search results

A total of 1,041 records were identified from eight databases: Embase (n = 135), PubMed (n = 102), Scopus (n = 107), Cochrane Library (n = 4), Web of Science (n = 76), CNKI (n = 177), VIP (n = 201), and Wanfang Data (n = 239). After removal of duplicates, 510 records remained. Following title and abstract screening, 101 reports were assessed in full text, of which 66 were excluded. Ultimately, 35 RCTs (21–55) were included. The study selection process is shown in the PRISMA 2020 flow diagram (Figure 1).

3.2Characteristics of included studies

A total of 35 RCTs involving 3,036 patients were included. Of these, 1,520 patients (50.1%) were assigned to the HBOT groups and 1,516 (49.9%) to the control groups. Study sample sizes ranged from 12 to 139 participants. The studies were published between 2014 and 2026, with 25 (71.43%) published in 2020 or later. Detailed study characteristics are presented in Table 1.

Table 1Characteristics of the included studies.

Study (Author, Year) Sample Size Gender (Male/Female) Age (years) Intervention Hyperbaric Oxygen Parameters Outcomes

E group C group E group C group E group C group E group C group Pressure (ATA) Total Interventions Duration (min)

Li (2026) (26) 52 52 30/22 28/24 61.54 ± 3.58 61.85 ± 3.70 HBOT+C Dual-Task Training+Conventional Intervention 2 30 100 MoCAMMSEMBI

Ren (2018) (53) 31 31 17/14 18/13 58.6 ± 6.8 59.2 ± 7.4 HBOT+C Basic Medication+Conventional Physical Rehabilitation 2 30 110 MoCAMMSE

Zhou (2024) (31) 44 44 24/20 23/21 59.25 ± 6.44 59.22 ± 6.47 HBOT+C Phased Physical Rehabilitation+Conventional Training 2 20 105 MoCAMMSENIHSS

Wang (2026) (39) 34 36 22/12 22/14 66.12 ± 13.45 62.43 ± 11.74 HBOT+C Conventional Treatment+Cognitive Training 1.8 30–42 90 MoCA

Yang (2024) (42) 49 46 27/22 20/26 71.29 ± 5.70 69.70 ± 4.54 HBOT+C Conventional Drugs+Donepezil 2.2 10 110 MoCAMMSE

Wang (2020) (44) 139 139 78/61 80/59 60.34 ± 3.82 60.25 ± 3.71 HBOT+C Conventional Pharmacotherapy+Donepezil Hydrochloride 2 20 110 MoCAMMSEBI

Zhang (2014) (49) 50 50 30/20 28/22 66.18 ± 6.89 66.10 ± 6.77 HBOT+C Conventional Pharmacotherapy 2 20 NR MoCA

Zhang (2021) (46) 42 42 25/17 22/20 62.05 ± 5.42 62.11 ± 7.56 HBOT+C Basic Treatment 2 20 NR MoCAMMSE

Qin (2026) (27) 40 40 NR NR NR NR HBOT+C Conventional Drugs+Cognitive Training+Physical Rehabilitation 2 20 NR MoCAMMSEMBI

Zhang (2026) (29) 51 51 23/28 27/24 63.04 ± 6.21 62.15 ± 5.09 HBOT+C Basic Pharmacotherapy+Comprehensive Rehabilitation+Donepezil Tablets 2 24 110 MoCAMMSE

ZhaoBo (2025) (22) 30 30 16/14 19/11 64.67 ± 6.58 65.21 ± 6.05 HBOT+C Basic Pharmacotherapy+Oxiracetam Capsules 2 24 60 MoCAMMSE

Ji (2023) (40) 84 84 42/42 44/40 43.28 ± 8.12 42.85 ± 7.75 HBOT+C Basic Pharmacotherapy+Butylphthalide Soft Capsules 2.0–2.5 40 120 MoCAMMSE

Wang (2018) (32) 50 50 24/26 28/22 73 ± 9 71 ± 12 HBOT+C Conventional Treatment+Oxiracetam 2.0216 30 60 MoCAMMSEBI

Zhou (2016) (38) 63 63 32/31 33/30 64.8 ± 9.6 65.8 ± 10.4 HBOT+C Conventional Pharmacotherapy+Oral Donepezil Hydrochloride 2 30 120 MoCA

Deng (2025) (37) 60 60 21/39 25/35 57.25 ± 3.51 56.35 ± 2.89 HBOT+C Basic Pharmacotherapy+Tenecteplase+Butylphthalide 2 24 NR MoCAMMSENIHSSBI

Guo (2024) (47) 14 12 10/4 7/5 53.86 ± 9.05 51.67 ± 11 HBOT+C Conventional Pharmacotherapy+Comprehensive Rehabilitation 2 20 100 MoCAMMSEMBI

Wang (2024) (36) 29 30 17/12 19/11 56.43 ± 14.50 58.59 ± 10.15 HBOT+C Basic Drugs+Comprehensive Rehabilitation+Scalp Acupuncture 2 24 105 MoCAMMSEMBI

Luo (2024) (54) 30 30 20/10 19/11 60.65 ± 4.73 60.58 ± 4.69 HBOT+C Basic Pharmacotherapy+"Zhi San Zhen” 2 30 105 MoCAMMSEBI

Yang (2020) (48) 29 29 20/9 22/7 58.41 ± 8.99 56.55 ± 8.53 HBOT+C Conventional Internal Medicine+Rehabilitation+Acupuncture 2 20 115 MoCAMBI

Yang (2019) (30) 30 30 15/15 13/17 52.14 ± 7.56 50.10 ± 6.21 HBOT+C Conventional Pharmacotherapy+Rehabilitation+Scalp Acupuncture 1.2 20 95 MoCAMMSE

Li (2024) (23) 50 50 32/18 30/20 61.2 ± 2.50 62.5 ± 2.20 HBOT+C Conventional Pharmacotherapy+Routine Rehab 2 20 115 MoCANIHSS

Zhan (2019) (51) 30 30 NR NR NR NR HBOT+C Conventional Pharmacotherapy+Routine Cognitive-Perceptual Training 2 40 120 MoCAMMSEADL

Xu (2025) (24) 33 34 18/15 24/10 53.58 ± 5.10 53.61 ± 4.53 HBOT+C Basic Pharmacotherapy+rTMS 2 12 105 MoCAMMSE

Wang (2021) (45) 46 46 26/20 27/19 64.59 ± 3.24 65.28 ± 3.16 HBOT+C Early Rehabilitation 2 20 85 MoCAMMSENIHSS

Liu (2026) (55) 30 27 22/8 15/12 51.9 ± 10.6 53.0 ± 11 HBOT+C Basic Treatment+Routine Cognitive Rehabilitation 1.8 20 100 MoCAMMSEADL

Yang (2022) (43) 50 50 26/24 28/22 59 ± 8 60 ± 8 HBOT+C Cognitive Training 2 14 120 MoCAMMSENIHSSADL

Zhong (2016) (50) 30 30 16/14 18/12 59.00 ± 7.83 58 ± 5.26 HBOT+C Conventional Clinical Drugs+Physical Rehabilitation 2 20 110 MoCAMMSE

Lu (2014) (33) 20 20 15/5 16/4 62.20 ± 7.55 61.72 ± 8.37 HBOT+C Basic Pharmacotherapy+Routine Rehab 2.2 20 105–110 MoCABI

DengNa (2025) (35) 40 40 26/14 23/17 49.94 ± 4.01 50.35 ± 3.76 HBOT+C Cognitive Function Training 2.5 20–28 115 MoCAMMSEMBINIHSS

Di (2020) (21) 40 40 19/21 18/22 57.8 ± 6.0 58.3 ± 5.6 HBOT+C Basic Pharmacotherapy+Routine Physical Rehabilitation 2 20 110 MoCAMMSEMBI

Qi (2021) (25) 36 36 NR NR 58.7 ± 7.9 59.3 ± 8.2 HBOT+C Conventional Pharmacotherapy+Physical Rehabilitation 2 40 110 MoCAMMSENIHSSBI

Lv (2020) (34) 46 46 29/19 26/20 46.35 ± 11.40 45.91 ± 10.23 HBOT+C Conventional Pharmacotherapy+Cognitive Training+Oxiracetam 1.2 20 100 MoCA

Duan (2018) (41) 45 45 23/22 26/19 58.3 ± 6.2 55.8 ± 6.7 HBOT+C Conventional Pharmacotherapy+Cognitive Training+rTMS 2 20 110 MoCA

RenYun (2018) (52) 27 27 13/14 15/12 58.6 ± 7.8 59.1 ± 7.3 HBOT+C Basic Drugs+Routine Rehabilitation 2 40 110 MoCAMMSE

Mu (2023) (28) 46 46 27/19 26/20 56.88 ± 5.11 56.96 ± 5.55 HBOT+C Conventional Pharmacotherapy+Cognitive Training+rTMS 2 20 110 MoCA

E group, HBOT group; C group, control group; ATA, atmospheres absolute; HBOT, Hyperbaric Oxygen Therapy; rTMS, repetitive transcranial magnetic stimulation; MoCA, Montreal Cognitive Assessment; MMSE, Mini-Mental State Examination; BI, Barthel Index; MBI, Modified Barthel Index; NIHSS, National Institutes of Health Stroke Scale; ADL, Activities of Daily Living; NR, not reported.

3.3Risk of bias assessment

The risk of bias in the 35 included RCTs was assessed using the Cochrane RoB 2 tool for the primary outcome, MoCA. As shown in Figure 2, one study (36) was judged to be at low risk of bias in the randomization process domain, while 34 had some concerns. In the deviations from intended interventions domain, one study (48) was judged to be at low risk, one (47) at high risk, and 33 had some concerns. All studies were judged to be at low risk in the domains of missing outcome data and measurement of the outcome, whereas all had some concerns regarding selection of the reported result. Overall, one study (47) was judged to be at high risk of bias and 34 had some concerns; none was judged to be at low risk.

3.4Outcome measures

3.4.1MoCA

All 35 studies reported MoCA scores. HBOT significantly improved MoCA scores compared with conventional treatment alone (MD = 2.90, 95% CI: 2.47–3.33; p < 0.00001; I2 = 84%; Figure 3).

3.4.2MMSE

26 studies (21, 22, 24–27, 29–32, 35–37, 40, 42–47, 50–55) involving 2,268 participants reported MMSE scores (HBOT, n = 1,137; control, n = 1,131). HBOT significantly improved MMSE scores compared with conventional treatment alone (MD = 2.68, 95% CI: 2.20–3.16; p < 0.00001; I2 = 83%; Figure 4).

3.4.3NIHSS

7 studies (23, 25, 31, 35, 37, 43, 45) involving 652 participants reported NIHSS scores (HBOT, n = 326; control, n = 326). HBOT significantly reduced NIHSS scores compared with conventional treatment alone (MD = −2.61, 95% CI: −3.34 to −1.89; p < 0.00001; I2 = 93%; Figure 5), indicating improved neurological function.

3.4.4MBI and BI

14 studies assessed activities of daily living, including eight (21, 26, 27, 35, 36, 38, 47, 48) using the MBI and six (25, 32, 33, 37, 44, 54) using the BI. Because the two instruments differ in item composition and scoring, they were analyzed separately. HBOT significantly improved MBI scores (MD = 6.64, 95% CI: 3.76–9.52; p < 0.00001; I2 = 82%; Figure 6) and BI scores (MD = 8.77, 95% CI: 4.72–12.82; p < 0.00001; I2 = 82%; Figure 6).

3.5Subgroup analysis

To further explore heterogeneity, subgroup analyses were performed according to the type of conventional treatment received by both the intervention and control groups.

3.5.1Subgroup analysis of MoCA

Subgroup analyses according to conventional treatment showed significant improvements in MoCA scores with adjunctive HBOT in the medication treatment (MD = 3.23, 95% CI: 2.15–4.31), physical rehabilitation (MD = 3.66, 95% CI: 2.63–4.70), cognitive rehabilitation (MD = 2.59, 95% CI: 1.98–3.20), and acupuncture (MD = 3.59, 95% CI: 3.00–4.18) subgroups (all p < 0.00001). Within-subgroup heterogeneity was high in the medication treatment (I2 = 92%) and cognitive rehabilitation (I2 = 75%) subgroups, moderate in physical rehabilitation (I2 = 51%), and absent in acupuncture (I2 = 0%). The rTMS subgroup contained only three studies and was therefore not included in the formal test for subgroup differences. No statistically significant difference was observed between subgroups (p = 0.10; I2 = 52.3%) (Figure 7).

3.5.2MMSE

Adjunctive HBOT significantly improved MMSE scores in the medication treatment (MD = 3.26, 95% CI: 1.96–4.55; p < 0.00001), physical rehabilitation (MD = 2.14, 95% CI: 0.21–4.08; p = 0.03), and cognitive rehabilitation (MD = 2.36, 95% CI: 1.81–2.92; p < 0.00001) subgroups. Within-subgroup heterogeneity remained high (I2 = 91, 84, and 73%, respectively), and the test for subgroup differences was not significant (p = 0.43, I2 = 0%; Figure 8).

3.6Meta-regression

Univariable random-effects meta-regression examined the associations of total HBOT sessions, baseline MoCA score, and HBOT treatment pressure with treatment effects. No significant associations were observed for treatment sessions (β = −0.0042, 95% CI: −0.0636-0.0552; p = 0.8892) or treatment pressure (β = −2.2548, 95% CI: −20.2214-15.7118; p = 0.8057). Baseline MoCA score showed a potential negative association with the treatment effect, with higher baseline MoCA scores tending to be associated with smaller treatment effects; however, this association did not reach statistical significance (β = −0.1411, 95% CI:-0.2903–0.0081; p = 0.0637; R2 = 15.42%). This association should be interpreted cautiously given the study-level nature of meta-regression.

3.7Sensitivity analysis and small-study effects

Leave-one-out sensitivity analyses showed consistent effect directions across all outcomes. In the MoCA physical rehabilitation subgroup, removal of one study reduced I2 from 51 to 0% without changing the effect direction.

Funnel plots and Egger’s tests showed no significant small-study effects for MoCA (p = 0.2364; Figure 9A) or MMSE (p = 0.7109; Figure 9B). Funnel plots and Egger’s tests were not performed for NIHSS, MBI, or BI because fewer than 10 studies were available.

3.8GRADE assessment of the certainty of evidence

The certainty of evidence for each outcome was assessed using the GRADEpro GDT tool. The certainty of evidence was low for MoCA, MMSE, and MBI and very low for NIHSS and BI. Downgrading was primarily due to risk of bias, inconsistency, and imprecision, with no serious concerns regarding indirectness. Detailed GRADE assessments are presented in Table 2.

Table 2GRADE assessment of the certainty of evidence for each outcome.

Certainty assessment Summary of findings

Participants (studies) Follow-up Risk of bias Inconsistency Indirectness Imprecision Publication bias Overall certainty of evidence Study event rates (%) Relative effect (95% CI) Anticipated absolute effects

With Conventional treatment without HBOT With Hyperbaric oxygen therapy (HBOT) Risk with Conventional treatment without HBOT Risk difference with Hyperbaric oxygen therapy (HBOT)

MoCA (assessed with: Montreal Cognitive Assessment; Scale from: 0 to 30)

3,036 (35 RCTs) Seriousa Seriousb Not serious Not serious None ⨁⨁◯◯Lowa,b 1,516 1,520 - 1,516 MD 2.9 higher (2.47 higher to 3.33 higher)

MMSE (assessed with: Mini–mental state examination; Scale from: 0 to 30)

2,268 (26 RCTs) Seriousa Seriousb Not serious Not serious None ⨁⨁◯◯Lowa,b 1,131 1,137 - 1,131 MD 2.68 higher (2.2 higher to 3.16 higher)

NIHSS (assessed with: National Institutes of Health Stroke Scale; Scale from: 0 to 42)

652 (7 RCTs) Seriousa seriousb not serious seriousc none ⨁◯◯◯Very lowa,b,c 326 326 - 326 MD 2.61 lower (3.34 lower to 1.89 lower)

MBI (assessed with: Modified Barthel Index; Scale from: 0 to 100)

613 (8 RCTs) Seriousa Seriousb Not serious Not serious None ⨁⨁◯◯Lowa,b 306 307 - 306 MD 6.64 higher (3.76 higher to 9.52 higher)

BI (assessed with: Barthel Index; Scale from: 0 to 100)

670 (6 RCTs) Seriousa Seriousb Not serious Seriousc None ⨁◯◯◯Very lowa,b,c 335 335 - 335 MD 8.77 higher (4.72 higher to 12.82 higher)

CI, confidence interval; MD, mean difference. a, downgraded one level for serious risk of bias; b, downgraded one level for serious inconsistency; c, downgraded one level for serious imprecision. GRADE certainty levels: ⊕⊕⊕⊕, high; ⊕⊕⊕◯, moderate; ⊕⊕◯◯, low; ⊕◯◯◯, very low.

3.9Adverse events

Six of the 35 included studies reported adverse events. In the HBOT groups, reported events mainly included gastrointestinal discomfort, nausea, insomnia, ear fullness, and ear pain. Control-group events mainly included acupuncture-related bleeding and vasovagal reactions. One study reported edema and dyspepsia in the HBOT group and myocardial infarction and pulmonary infection in the control group. Given the limited reporting, the available data were insufficient to comprehensively assess the safety of HBOT (56).

4Discussion

4.1Main findings

This systematic review included 35 randomized controlled trials involving 3,036 patients with PSCI and evaluated the effects of adjunctive HBOT on cognitive, neurological, and functional outcomes. Overall, HBOT added to conventional treatment was associated with improvements in MoCA and MMSE scores and was associated with favorable effects on NIHSS, MBI, and BI. These findings suggest that HBOT may provide additional benefits for cognitive and functional recovery in patients with PSCI.

The consistent improvements in MoCA and MMSE are broadly consistent with previous evidence suggesting potential cognitive benefits of HBOT in neurological disorders (57). Notably, the pooled improvement in MoCA (MD = 2.90 points) exceeded previously reported MCID estimates of 1.0–2.15 points in stroke populations, suggesting potential clinical relevance (58, 59). However, previous studies have reported heterogeneous effects across diseases, cognitive domains, and treatment protocols. The present review specifically focused on PSCI and included only RCTs, providing more direct evidence regarding the potential adjunctive role of HBOT in this population.

The favorable effects on NIHSS, MBI, and BI suggest that the potential benefits of HBOT may extend beyond cognition to neurological function and activities of daily living. Differences from previous HBOT studies in acute ischemic stroke may reflect differences in patient populations, treatment objectives, and the use of HBOT as an adjunct to rehabilitation. Therefore, these findings should not be extrapolated to HBOT as a treatment for acute stroke reperfusion.

4.2Potential mechanisms

HBOT may facilitate post-stroke neurological recovery by increasing cerebral oxygen availability and modulating the post-ischemic microenvironment. Potential mechanisms include modulation of oxidative stress, inflammation, apoptosis, mitochondrial function, and neurovascular remodeling, which may contribute to recovery of injured neural tissue (57).

HBOT may also influence neuroplasticity and functional brain-network reorganization. One RCT included in this review reported that HBOT combined with cognitive training improved MMSE and BI scores and enhanced functional connectivity involving the left dorsolateral prefrontal cortex and Broca’s area; changes in functional connectivity were correlated with MMSE improvement (55). These findings suggest a possible association between functional connectivity changes and cognitive improvement following adjunctive HBOT, although the mechanistic significance of this association remains uncertain.

Importantly, HBOT should be considered an adjunctive rather than a replacement therapy. Most included studies compared HBOT plus conventional treatment with conventional treatment alone, and therefore primarily evaluated the incremental effects of adding HBOT to conventional treatment.

4.3Heterogeneity

Substantial heterogeneity was observed across the major outcomes. Subgroup analyses suggested that conventional treatment type might contribute to the heterogeneity in MoCA effects; however, the difference between subgroups was not statistically significant. Substantial residual heterogeneity remained in several subgroups, indicating that treatment type alone could not fully account for the observed variability. In contrast, no significant subgroup differences were observed for MMSE.

Meta-regression identified baseline MoCA score as a potential study-level moderator, with higher baseline MoCA scores tending to be associated with smaller treatment effects, explaining approximately 15.42% of the between-study variance. No significant associations were observed for the number of HBOT sessions or treatment pressure. These findings should be interpreted cautiously because meta-regression is based on study-level rather than individual-level data and does not establish effect modification at the patient level.

The results suggest that baseline cognitive status may contribute to variation in treatment effects, but the current evidence is insufficient to define an optimal target population. Future trials should stratify patients according to baseline cognitive severity, and individual participant data meta-analysis may help clarify potential effect modifiers.

4.4Robustness and certainty of evidence

Sensitivity analyses showed consistent effect directions across outcomes, suggesting that the findings were not driven by individual studies. However, substantial heterogeneity persisted across outcomes and within most subgroups. Meta-regression identified baseline MoCA as a potential source of heterogeneity, but it explained only 15.42% of the between-study variance. Thus, most heterogeneity remained unexplained, and the pooled estimates should be interpreted cautiously (18, 60). The certainty of evidence was low for MoCA, MMSE, and MBI and very low for NIHSS and BI, further limiting confidence in the estimated effects.

Only six studies reported adverse events, limiting the assessment of HBOT-related risks. The absence of reported adverse events in other studies does not establish their absence (56). Previous evidence has also identified HBOT-related adverse effects, particularly ear discomfort (61). Furthermore, although funnel plots and Egger’s tests did not detect significant small-study effects for MoCA or MMSE, publication bias cannot be excluded because these methods have limited power. The exclusively Chinese evidence base may also limit generalizability.

4.5Clinical implications

The findings of this review suggest that adjunctive HBOT may have potential benefits for cognitive and functional recovery in patients with PSCI. However, the clinical implications of these findings should be interpreted cautiously. Most included studies compared HBOT plus conventional treatment with conventional treatment alone; therefore, the observed effects represent the potential incremental benefits of adding HBOT to existing care rather than its effects as a standalone treatment.

The applicability of these findings to international clinical practice remains uncertain, as all included studies were conducted in China. Differences in patient characteristics, diagnostic criteria for PSCI, HBOT protocols, and concomitant rehabilitation practices across healthcare settings may influence treatment responses and the interpretation of pooled effect estimates. In particular, differences in cognitive assessment thresholds may affect the characteristics of enrolled patients, while variation in background treatments may influence the incremental benefits associated with HBOT. These potential differences were not directly evaluated in this review and should not be interpreted as established differences between China and other countries.

Furthermore, substantial between-study heterogeneity and low-to-very-low certainty of evidence limit confidence in the pooled estimates. Although the findings suggest potential benefits of adjunctive HBOT, they do not establish its effectiveness across different populations or healthcare systems. The current evidence therefore does not support the routine use of HBOT in all patients with PSCI. Future well-designed, multicenter randomized controlled trials involving diverse populations and healthcare settings, with standardized diagnostic criteria, clearly reported HBOT protocols, and systematic safety monitoring, are needed to establish its clinical applicability.

4.6Limitations

Several limitations should be acknowledged. First, methodological limitations, particularly difficulties in blinding, may have affected the reliability of the findings. Second, substantial clinical heterogeneity remained largely unexplained despite subgroup analyses and meta-regression. Third, incomplete reporting of HBOT parameters and limited long-term follow-up restricted the assessment of dose–response relationships and the durability of treatment effects. Fourth, only six of the 35 included studies reported adverse events, limiting safety assessment and precluding the exclusion of unreported rare or serious events (61). Fifth, all included studies were conducted in China, limiting the generalizability of the findings. Although funnel plots and Egger’s tests detected no significant small-study effects for MoCA or MMSE, publication bias cannot be excluded because these methods have limited power.

5Conclusion

Adjunctive HBOT may provide additional cognitive and functional benefits in patients with PSCI. However, substantial between-study heterogeneity, low-to-very-low certainty of evidence, and the exclusively Chinese evidence base jointly warrant cautious interpretation and limit the applicability of the findings to international clinical practice. Large, well-designed randomized controlled trials involving diverse populations, with long-term follow-up and systematic safety monitoring, are needed to confirm the effects and safety of adjunctive HBOT in patients with PSCI.

References

1.Feigin VL Stark BA Johnson CO Roth GA Bisignano C Abady GG . Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the global burden of disease study 2019 . Lancet Neurol . (2021 ) 20 :795 –820 . doi: 10.1016/S1474-4422(21)00252-0 , 34487721 PMC8443449

2.Feigin VL Brainin M Norrving B Martins SO Pandian J Lindsay P . World stroke organization: global stroke fact sheet 2025 . Int J Stroke . (2025 ) 20 :132 –44 . doi: 10.1177/17474930241308142 , 39635884 PMC11786524

3.He A Wang Z Wu X Sun W Yang K Feng W . Incidence of post-stroke cognitive impairment in patients with first-ever ischemic stroke: a multicenter cross-sectional study in China . Lancet Reg Health West Pac . (2023 ) 33 :100687 . doi: 10.1016/j.lanwpc.2023.100687 , 37181529 PMC10166998

4.Weaver NA Kuijf HJ Aben HP Abrigo J Bae HJ Barbay M . Strategic infarct locations for post-stroke cognitive impairment: a pooled analysis of individual patient data from 12 acute ischaemic stroke cohorts . Lancet Neurol . (2021 ) 20 :448 –59 . doi: 10.1016/S1474-4422(21)00060-0 , 33901427

5.El HN Katzan IL Rost NS Blake ML Byun E Pendlebury ST . Cognitive impairment after ischemic and hemorrhagic stroke: a scientific statement from the American Heart Association/American Stroke Association . Stroke . (2023 ) 54 :e272 –91 . doi: 10.1161/STR.0000000000000430 PMC12723706 37125534

6.Filler J Georgakis MK Dichgans M . Risk factors for cognitive impairment and dementia after stroke: a systematic review and meta-analysis . Lancet Healthy Longev . (2024 ) 5 :e31 –44 . doi: 10.1016/S2666-7568(23)00217-9 , 38101426

7.Li H Zhao Z Qiao P Wang J Xu P Ye Y . Meta-analysis of treatment methods for poststroke cognitive impairment: a network analysis of various interventions . Brain Behav . (2026 ) 16 :e71115 . doi: 10.1002/brb3.71115 , 41581201 PMC12832102

8.Gao Y Qiu Y Yang Q Tang S Gong J Fan H . Repetitive transcranial magnetic stimulation combined with cognitive training for cognitive function and activities of daily living in patients with post-stroke cognitive impairment: a systematic review and meta-analysis . Ageing Res Rev . (2023 ) 87 :101919 . doi: 10.1016/j.arr.2023.101919 , 37004840

9.Han JZ Yang Y Wang YF Feng JH Song CN Wu WJ . Effectiveness and safety of governor vessel acupuncture therapy for post-stroke cognitive impairment: a meta-analysis of randomized controlled trials . Ageing Res Rev . (2024 ) 99 :102355 . doi: 10.1016/j.arr.2024.102355 , 38942201

10.Hu J Cheng Y Qiao Y Zhou J Cai M . Impact of hyperbaric oxygen therapy on serum lipid profiles and cognitive recovery in patients with post-stroke cognitive impairment: a retrospective cohort study . Am J Transl Res . (2026 ) 18 :4326 –45 . doi: 10.62347/MLOM4923 , 42325781 PMC13275875

11.Lu L Zhao L Xie Y Wang L Ji Y Luo X . Research hotspots and trends of hyperbaric oxygen therapy in stroke: bibliometrics and visual analysis . Med Gas Res . (2026 ) 16 :380 –8 . doi: 10.4103/mgr.MEDGASRES-D-25-00063 , 41575017 PMC13456481

12.Zhai WW Sun L Yu ZQ Chen G . Hyperbaric oxygen therapy in experimental and clinical stroke . Med Gas Res . (2016 ) 6 :111 –8 . doi: 10.4103/2045-9912.184721 , 27867477 PMC5110133

13.Gottfried I Schottlender N Ashery U . Hyperbaric oxygen treatment-from mechanisms to cognitive improvement . Biomolecules . (2021 ) 11 :1520 . doi: 10.3390/biom11101520 , 34680155 PMC8533945

14.Lippert T Borlongan CV . Prophylactic treatment of hyperbaric oxygen treatment mitigates inflammatory response via mitochondria transfer . CNS Neurosci Ther . (2019 ) 25 :815 –23 . doi: 10.1111/cns.13124 , 30972972 PMC6630002

15.Boussi-Gross R Golan H Volkov O Bechor Y Hoofien D Beeri MS . Improvement of memory impairments in poststroke patients by hyperbaric oxygen therapy . Neuropsychology . (2015 ) 29 :610 –21 . doi: 10.1037/neu0000149 , 25384125

16.Gao B Peng M Chen F Peng X Huang K Li Q . Hyperbaric oxygen attenuates cerebral ischemia-reperfusion injury in rats by modulating sodium channels . Dev Neurobiol . (2025 ) 85 :e22974 . doi: 10.1002/dneu.22974 , 40572015

17.BenAri O Efrati S Hadanny A Sano M Bendlin BB Lin H . A double-blind placebo-controlled clinical trial testing the effect of hyperbaric oxygen therapy on brain and cognitive outcomes of mildly cognitively impaired elderly with type 2 diabetes: study design . Alzheimer's & Dementia . (2020 ) 6 :e12008 . doi: 10.1002/trc2.12008 , 32296731 PMC7153432

18.Li X Lu L Min Y Fu X Guo K Yang W . Efficacy and safety of hyperbaric oxygen therapy in acute ischaemic stroke: a systematic review and meta-analysis . BMC Neurol . (2024 ) 24 :55 . doi: 10.1186/s12883-024-03555-w , 38308217 PMC10837997

19.Liang XX Hao YG Duan XM Han XL Cai XX . Hyperbaric oxygen therapy for post-stroke depression: a systematic review and meta-analysis . Clin Neurol Neurosurg . (2020 ) 195 :105910 . doi: 10.1016/j.clineuro.2020.105910 , 32474256

20.Gao M Huang L Yi J Zhang T Zhu G Zhang Q . The effectiveness of computerized cognitive training in patients with poststroke cognitive impairment: systematic review and meta-analysis . J Med Internet Res . (2025 ) 27 :e73140 . doi: 10.2196/73140 , 40503808 PMC12203030

21.Di Zhao . An observation on the efficacy of hyperbaric oxygen therapy combined with cognitive training in treating post-stroke cognitive impairment [in Chinese] . China Sci Technol J Database Med Pharm . (2020 ) 10 :84 .

22.Bo Z . Effect of hyperbaric oxygen combined with oxiracetam treatment on cognitive function and cerebral hemodynamic indicators in patients with post-stroke cognitive impairment [in Chinese] . Reflexol Rehabil Med . (2025 ) 6 :107 –10 . doi: 10.16344/j.cnki.10-1669/r4.2025.03.022

23.Cuiling L Yuhua L Xiang L Hongyan Z Wenli L Yang F . Efficacy of hyperbaric oxygen combined with acupuncture in the treatment of cerebral infarction and its impact on motor and cognitive function in patients [in Chinese] . Tradit Chin Med . (2024 ) 13 :3090 –6 . doi: 10.12677/tcm.2024.1311456

24.Da X Xiaobin Z Yuhui H Qingjin L . Effects of hyperbaric oxygen therapy at different frequencies combined with RTMS on cerebral hemodynamic parameters and cognitive function in patients with cerebral infarction [in Chinese] . Clinical Misdiagnosis and Mistherapy . (2025 ) 38 :26 –31 . doi: 10.3969/j.issn.1002-3429.2025.24.005

25.Fei Q Yanling S Hui Z . Efficacy of hyperbaric oxygen combined with repetitive transcranial magnetic stimulation on patients with cognitive impairment after cerebral infarction and its effect on hemodynamics [in Chinese] . Zhongguo Hang Hai Yi Xue Gao Ya Yi Xue Za Zhi . (2021 ) 28 :383 –8 . doi: 10.3760/cma.j.cn311847-20201117-00426

26.Gang L Jian H . Application of hyperbaric oxygen combined with dual-task training in patients with post-stroke cognitive impairment [in Chinese] . Zhongguo Kang Fu Yi Xue Za Zhi . (2026 ) 35 :36 –9 . doi: 10.13517/j.cnki.ccm.2026.05.007

27.Guiyan Q . Analysis of the efficacy of hyperbaric oxygen therapy as an adjuvant treatment for cognitive impairment following ischemic stroke [in Chinese] . China Sci Technol J Database . (2026 ) 3 :50 –3 .

28.Lan M . Improvement of cognitive function in patients with cerebral infarction by hyperbaric oxygen combined with repeated transcranial magnetic stimulation [in Chinese] . Contemp Med . (2023 ) 29 :116 –8 .

29.Liang Z Jingzhong W Jiuzeng J Quande D . Therapeutic effect of hyperbaric oxygen combined with donepezil in the treatment of 51 cases of mild to moderate cognitive dysfunction after stroke [in Chinese] . Chin J Naut Med Hyperbaric Med . (2026 ) 33 :265 –70 . doi: 10.3760/cma.j.cn311847-20241024-00252

30.Lin Y Jie T Li-zao C . Clinical study on scalp acupuncture combined with hyperbaric oxygen for cognition disorders after stroke [in Chinese] . Guid J Tradit Chin Med Pharm . (2019 ) 25 :36 –8 . doi: 10.13862/j.cnki.cn43-1446/r.2019.24.012

31.Litao Z Xiaoda WU Tiantian S . Effect analysis of phased rehabilitation training combined with hyperbaric oxygen in the treatment of hemiplegia patients after cerebral hemorrhage [in Chinese] . Chin J Trauma Disabil Med . (2024 ) 32 :126 –9 .

32.Miaomiao W Jinjun L Li W Fangkuang J Xianghong S . Effect and safety of oxiracetam combined with hyperbaric oxygen treatment on cognitive impairment after cerebral infarction [in Chinese] . China Med . (2018 ) 13 :1661 –5 . doi: 10.3760/j.issn.1673-4777.2018.11.016

33.Min L Wei-wei L Lu X . Efficacy of computer aided training combined with hyperbaric oxygen therapy on stroke pa-tients with cognitive dysfunction [in Chinese] . Neural Inj Funct Reconstr . (2014 ) 6 :478 –81 . doi: 10.3870/sjsscj.2014.06.008

34.Ming-xin L Shuang-jie L Yu-qin W Jun-jun L Ting-ting L . Effects of 10hz high-frequency repetitive transcranial magnetic stimulation combined with hyperbaric oxygen on cognitive dysfunction and cerebral metabolism after stroke [in Chinese] . Chin J Microcirc . (2020 ) 30 :26 –31 . doi: 10.3969/j.issn.1005-1740.2020.04.006

35.Na D Chunlai L Lei Z Tengjiao H Qiong L . The efficacy of hyperbaric oxygen therapy combined with cognitive training on neurological function in patients with cognitive impairment following ischemic stroke within 6 months [in Chinese] . Jian Kang Zhong Gao . (2025 ) 19 :106 –108, 123 .

36.Nianhua W . Clinical Study of Hyperbaric Oxygen Combined with Head Acupuncture in Treatment of Cognitive Impairment after Stroke of Blood Stagnation type [in Chinese] [Master’s]. Wuhan, Hubei: Hubei University of Chinese Medicine. (2024 ).

37.Qiao D Xiaomin L Lin B Boding W Feiyu C . Efficacy of hyperbaric oxygen combined with tenaiplase and butylphthalide in the treatment of vascular cognitive impairment after acute ischemic stroke [in Chinese] . Chin J Health Manag . (2025 ) 32 :1141 –5 . doi: 10.3760/cma.j.cn311847-20250121-00022

38.Shasha Z . An observation on the efficacy of donepezil hydrochloride combined with hyperbaric oxygen therapy for vascular cognitive impairment following stroke [in Chinese] . Chin J Pract Nerv Dis . (2016 ) 19 :63 –4 .

39.Shuili W Dongzhang X Chunmei X Jingjing L Shiquan Y Hanchun W . Effect of hyperbaric oxygen on inflammatory microenvironment regulation and cognitive rehabilitation in patients with cognitive impairment after intracerebral hemorrhage [in Chinese] . Chin J Naut Med Hyperbaric Med . (2026 ) 33 :276 –80 . doi: 10.3760/cma.j.cn311847-20250323-00083

40.Weidong J Chunyu W Haiyun Z Qingsong Y Ying Z . Clinical efficacy of hyperbaric oxygen combined with n - butylphthalide in the treatment of ischemic stroke due to atherosclerosis of aorta and its effect on cognitive function [in Chinese] . Chin J Naut Med Hyperbaric Med . (2023 ) 30 :357 –60 .

41.Xiaodong D Fang-yuan X Zehua X . Effects of hyperbaric oxygen combine with repetitive transcranial magnetic stimulation treatment on the cognitive ability in patients with cognitive impairment after ischemic stroke [in Chinese] . Chin J Rehabil Med . (2018 ) 33 :1168 –72 . doi: 10.3969/j.issn.1001-1242.2018.10.007

42.Xiaoling Y Tianyi R Zhenyu W Lei C Miao C Zuoting S . The effects of hyperbaric oxygen therapy on cognitive function and inflammatory factors in patients with acute cerebral infarction complicated by cognitive impairment [in Chinese] . Chin J Integr Med Cardio Cerebrovasc Dis . (2024 ) 22 :557 –60 . doi: 10.12102/j.issn.1672-1349.2024.03.030

43.Xiaoling Y Zhenyu W Zuoting S Tianyi R Min W Miao C . The effects of hyperbaric oxygen therapy combined with cognitive training on neurological function in patients with post-stroke cognitive impairment [in Chinese] . Shanxi Med J . (2022 ) 51 :1973 –6 . doi: 10.3969/j.issn.0253-9926.2022.17.014

44.Xipei W Qingli D Yanan G . An observation on the efficacy of hyperbaric oxygen therapy for post-stroke cognitive impairment [in Chinese] . J Qiqihar Univ Med . (2020 ) 41 :2011 –3 . doi: 10.3969/j.issn.1002-1256.2020.16.011

45.Xuedong W . Effect of early rehabilitation training and hyperbaric oxygen therapy on the neurological function and cognitive function of patients with hypertensive intracerebral hemorrhage after minimally invasive surgery [in Chinese] . Reflexol Rehabil Med . (2021 ) 2 :54 –6 .

46.Xuejun Z Wenjin Z Xiaoyu Y . An analysis of the efficacy of hyperbaric oxygen therapy in patients with acute cerebral infarction and cognitive impairment and its impact on their cognitive function [in Chinese] . Health Guide . (2021 ) 28 :58 .

47.Yanglu G Chenyang M Ke S Yuwen S Yajun M . An observation on the efficacy of the “awaken the mind and open the orifices” acupuncture method combined with hyperbaric oxygen therapy in treating cognitive impairment following stroke [in Chinese] . Zhejiang Clin Med J . (2024 ) 26 :1142 –4 .

48.Yong-kai Y Fan Z Xiao-hui Z Hao W Sheng-hui L . The effect of hyperbaric oxygen combined with acupuncture on cognitive function of patients with cerebral infarction in recovery period [in Chinese] . Guide of China Medicine . (2020 ) 18 :7 –9 . doi: 10.15912/j.cnki.gocm.2020.17.004

49.Yue-rong Z Gui-mei Y . The influence of hyperbaric oxygenation on cognitive function in patients with lacunar infarction nursing experience [in Chinese] . Chin J Gen Pract . (2014 ) 12 :818 –9 . doi: 10.16766/j.cnki.issn.1674-4152.2014.05.020

50.Yufei Z Wenguang X Ting X Rong L . An observation on the efficacy of hyperbaric oxygen therapy combined with cognitive training in treating post-stroke cognitive impairment [in Chinese] . Chin J Rehabil Med . (2016 ) 31 :298 –300 . doi: 10.3870/zgkf.2016.04.020

51.Yuhua Z . Hyperbaric oxygen therapy combined with acupoint thread implantation for the treatment of post-stroke cognitive impairment [in Chinese] . Chinese Sci Technol J Database . (2019 ) 1 :265 –6 .

52.Yun R Xudong G Yunhai Y Jianming F Hankui Y Liang L . An observation on the efficacy of hyperbaric oxygen therapy in the treatment of cognitive impairment following ischemic stroke [in Chinese] . Chin J Naut Med Hyperbaric Med . (2018 ) 25 :177 –9 .

53.Yun R Xudong G Yunhai Y Jianming F Hankui Y Liang L . The effect of hyperbaric oxygen therapy combined with repetitive transcranial magnetic stimulation on patients with cognitive dysfunction after cerebral infarction [in Chinese] . Chin J Phys Med Rehabil . (2018 ) 40 :336 –9 .

54.Zengyuan L Jun L Jielin H Jiao L Jianzhong X . Effect of "Zhisanzhen" combined with hyperbaric oxygen on cognitive function and activities of daily living in patients with vascular cognitive impairment after cerebral infarction [in Chinese] . China Mod Med . (2024 ) 31 :92 –5 .

55.Liu J Han T Yan C Ma Q Yuan L Ge S . Hyperbaric oxygen therapy combined with computerized cognitive training improves global cognition and functional independence post-stroke: a randomized controlled trial . J Neuroeng Rehabil . (2026 ) 23 :192 . doi: 10.1186/s12984-026-01992-x , 42050669 PMC13270702

56.Zhang Y Zhou Y Jia Y Wang T Meng D . Adverse effects of hyperbaric oxygen therapy: a systematic review and meta-analysis . Front Med . (2023 ) 10 :1160774 . doi: 10.3389/fmed.2023.1160774 , 37275378 PMC10232961

57.Marcinkowska AB Mankowska ND Kot J Winklewski PJ . Impact of hyperbaric oxygen therapy on cognitive functions: a systematic review . Neuropsychol Rev . (2022 ) 32 :99 –126 . doi: 10.1007/s11065-021-09500-9 , 33847854 PMC8888529

58.Wu C Hung S Lin K Chen K Chen P Tsay P . Responsiveness, minimal clinically important difference, and validity of the Moca in stroke rehabilitation . Occup Ther Int . (2019 ) 2019 :2517658 . doi: 10.1155/2019/2517658 , 31097928 PMC6487084

59.Lindvall E Abzhandadze T Quinn TJ Sunnerhagen KS Lundström E . Is the difference real, is the difference relevant: the minimal detectable and clinically important changes in the Montreal cognitive assessment . Cereb Circ Cogn Behav . (2024 ) 6 :100222 . doi: 10.1016/j.cccb.2024.100222 , 38745691 PMC11090903

60.Bennett MH Weibel S Wasiak J Schnabel A French C Kranke P . Hyperbaric oxygen therapy for acute ischaemic stroke . Cochrane Database Syst Rev . (2014 ) 2014 :CD4954 . doi: 10.1002/14651858.CD004954.pub3 , 25387992 PMC10754477

61.Golder S Loke YK Wright K Norman G . Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review . PLoS Med . (2016 ) 13 :e1002127 . doi: 10.1371/journal.pmed.1002127 , 27649528 PMC5029817

Come citare questo studio

Xiaosai Hu, Shurong Zhao, Dandan Zhang, Xianguo Meng. (2026). Adjunctive hyperbaric oxygen therapy for post-stroke cognitive impairment: a systematic review and meta-analysis of randomized controlled trials.. Frontiers in neurology. DOI: 10.3389/fneur.2026.1982226

Consulta la pubblicazione originale ↗